To evaluate tubular damage in diabetic patients, we measured the 24h urinary excretion of five enzymes ( N-acetyl-8-D-glucosaminidase, y-glutam yl transpeptidase, dipeptidyl aminopeptidase IV, alanine aminopeptidase and alkaline phosphatase) that originate in renal proximal tubular cells. 2. Studies were performed on 118 non-insulindependent diabetic patients, 59 nondiabetic patients with chronic renal disease and 47 normal control subjects. First, the correlation between renal function, glycaemic control and urinary enzyme excretion was investigated. Secondly, the subjects were treated by controlled diet therapy to assess the effects of better glycaemic control on urinary enzyme excretion. 3. Regardless of a diabetic or nondiabetic cause of renal dysfunction, all of the five enzymes showed abnormal urinary excretion in patients with renal insufficiency (serum creatinine concentration > 2.0 mg/dl). In diabetic patients, however, an increase in N-acetyl-/3-D-glucosaminidase excretion and a decrease in y-glutamyl transpeptidase excretion were noted even in those who had no signs of renal dysfunction, including microalbuminuria. Moreover, the excretion of these two enzymes had a higher degree of correlation with glycaemic control and renal function than did that of the other three enzymes. Multiple regression analysis revealed that excretion of N-acetyl-/I-D-glucosamindase is best correlated with urinary protein (2 = 0.33, whereas excretion of y-glutamyl transpeptidase is closely associated with glomerular filtration rate (13 = 0.33).
INTRODUCTION
The natural history of diabetic nephropathy is well known: the first appearance of microalbuminuria is followed by overt proteinuria, and gradually develops into renal failure [ 13. These processes have been explained mainly by glomerular changes. However, Bohle and co-workers [2, 31 have emphasized the importance of tubulo-interstitial changes rather than glomerular lesions in the progression of chronic renal failure. Their results strongly suggest that tubulo-interstitial changes develop in the earliest stages of diabetic nephropathy. Currently, the excretion of /-?,-microglobulin or other tubular proteins is measured in order to estimate tubular damage. However, abnormal values are found only in patients with advanced renal disease. In this regard, we focused on the various enzymes that originate in the renal tubules. If tubulo-interstitial changes precede the glomerular alterations and are reflected in the urinary excretion of certain enzymes, they would be especially helpful in predicting the clinical course of renal disease. Therefore, we measured the 24h urinary excretion of five enzymes in non-insulindependent diabetic patients and attempted to elucidate tubular damage in this disease process. from those attending Keio University Hospital, Tokyo, according to the classification of the National Diabetes Data Group [4] . Patients who may have had non-diabetic causes of renal disease were excluded by history. Patients with cellular casts or recurrent microscopic haematuria were also excluded. None of the patients had ever been treated with oral hypoglycaemic drugs or insulin. They were divided into three groups according to their renal function. The first group (diabetic patients with normal renal function, NF/DM) consisted of 47 patients with normal serum creatinine levels (males S 1.3 mg/dl, females 5 1.1 mg/dl) and normal urinary albumin excretion rates ( 20 pg/ min). The second group (diabetic patients with intermediate renal function, IF/DM) consisted of 45 patients with elevated serum creatinine levels (not greater than 2.0mg/dl). Patients with normal serum creatinine levels but elevated urinary albumin excretion rates ( > 20pg/min) were also included in this group. The third group (diabetic patients with renal failure, RF/DM) was made up of 26 patients whose serum creatinine levels were above 2.0mg/dl. As their non-diabetic control groups, 47 healthy subjects matched for sex and age with the NF/DM group and 59 non-diabetic patients with chronic renal disease were also studied.
Diabetes mellitus was excluded by a 75g oral glucose tolerance test. The healthy subjects showed no abnormalities on routine medical checkups and fulfilled the renal condition of NF/DM. They served as a normal control group (NL). In the non-diabetic patients with chronic renal disease, urinary tract infection, drug-induced nephropathy, neoplasms, obstructive renal disease and hereditary renal disease were excluded by history and appropriate laboratory investigations. They were divided into two groups (intermediate renal function or IF, n=34, and renal failure or RF, n=25) using the same criteria for renal function as in the diabetic groups. All the subjects were hospitalized for a short time for the controlled diet and complete 24 h urine collection (study A) and, where possible, for a longer time to study the effects of the diet therapy (study B). Written informed consent was obtained from all subjects before they were enrolled in the trial.
Experimental protocol
Study A. After 3-5 days of hospitalization and diet therapy (105 kJ day-' kg-' in standard body weight, approximately 55% carbohydrate, 15% protein, 30% fat), studies were carried out on 3 consecutive days. Urine was collected every day from 07.00 to 07.00 hours in plastic containers stored in a refrigerator at 4°C and a sample was centrifuged immediately for 10min at 1500g. Part of it was reserved for the measurement of urinary sugar, urinary protein, creatinine concentration, urinary microalbumin and urinary /3,-microglobulin. The remainder was dialysed against pure water for 12 h.
After the dialysis, we measured the activities of Nacetyl-P-D-glucosaminidase (NAG), y-glutamyl transpeptidase (GGTP), dipeptidyl aminopeptidase IV (DAP IV), alanine aminopeptidase (AAP) and alkaline phosphatase (ALP). Then we calculated the total enzyme activity of the 24h urine sample. The completeness of urine collection was confirmed by the total creatinine excretion ( 2 14mg/kg for males and 2 11 mg/kg for females, both in standard body weight) and incomplete samples were excluded. On each day of the study we also measured blood pressure, fasting plasma glucose concentration and serum creatinine concentration. Creatinine clearance was calculated as a measurement of glomerular filtration rate. Mean blood pressure was defined as diastolic pressure plus one-third of the pulse pressure. These values obtained each day were averaged and used for analysis. HbA,, was measured on the first day of the study.
Study B. Among the patients in study A, 32 NF/ DM patients (male/female= 14/18) and the same number of sex-and age-matched normal control subjects, 27 IF/DM patients (12/15), 17 RF/DM patients (10/7), 20 I F patients (9/11) and 17 R F patients (9/8) were studied again after 2-4 weeks of hospitalization and diet therapy (84-105 kJ day-' kg-' in standard body weight, mean 20 days). The methods of sample collection and measurements were the same as in study A. The effects of diet therapy on the urinary excretion of five enzymes, microalbumin and P,-microglobulin were studied.
Analytical methods
Plasma and urinary glucose concentrations were determined by the glucose oxidase method on a Glucoroder-MkII (Analytical Instruments Inc., Tokyo, Japan). HbA,, was measured by a chromatographic technique (normal range 4.1-6.4%) [S] . Urinary protein was measured by the Pyrogallol Red-molybdate method (Micro TP-Test; Wako Pure Chemical Industries, Osaka, Japan). Creatinine concentration was determined by Jaffe's method. Concentrations of albumin (Albumin RIA; Pharmacia, Uppsala, Sweden) and mic micro globulin (p,-micro RIA; Pharmacia) were measured by specific radioimmunoassays. The detection limit of both assays was 0.2 mg/l.
Enzyme assays
Urinary activities of the five enzymes were assayed as follows.
(1) NAG (EC 3.2.1.30) activity was determined by a spectrophotometric assay using sodio m-cresolsulphonaphthaleinyl N-acetyl-P-D-glucosaminide as substrate [6] .
(2) GGTP (y-glutamyltransferase, EC 2.3.2.2) activity was determined by a spectrophotometric assay [7] under the conditions recommended by the (3) DAP IV (dipeptidyl peptidase IV, EC 3.4.14.5) activity was measured by the fluorimetric method of Kato et al. [9] . The fluorogenic substrate (7-glycylproline-4-methylcoumarinamide tosylate) was obtained from the Peptide Institute Inc., Osaka, Japan.
(4) AAP (microsomal aminopeptidase, EC 3.4.1 1.2) activity was measured by a spectrophotometric assay using ~-alanine-4-nitroanilide as the substrate [lo] .
(5) ALP (EC 3.1.3.1) activity was determined by a spectrophotometric assay originally described by Kind and King [l I ] .
Statistical analysis
Results are expressed as means & SEM. Urinary data were analysed by the Wilcoxon signed-rank test, Mann-Whitney U-test or Kruskal-Wallis test as appropriate. Other data were analysed by a paired t-test, unpaired t-test or analysis of variance. Multiple regression analysis was performed by the stepwise forward-selection method. When a pair of variables showed a high degree of correlation ( I 20.7), only the most significant factor was chosen to avoid multi-co-linearity. All the statistical computations were carried out with StatView I1 (Abacus Concepts Inc., Berkeley, CA, U.S.A.) on a Macintosh IIci computer (Apple Computer Inc., Cupertino, CA, U.S.A.).
RESULTS

Study A urinary enzyme excretion in non-insulindependent diabetic patients and non-diabetic patients with chronic renal disease
The characteristics of the diabetic patients, nondiabetic patients with chronic renal disease and normal control subjects are shown in Table 1 . Diabetic patients were characterized by significantly higher fasting plasma glucose concentration and urinary sugar. Compared with normal control subjects, NF/DM patients showed no difference in mean blood pressure and renal function, including urinary microalbumin and /?,-microglobulin excretion. Also, there were no differences in these parameters between IF/DM or RF/DM patients and their respective non-diabetic controls. Urinary excretion of microalbumin and /?,-microglobulin was significantly elevated only in RF/DM and RF patients.
Urinary enzyme excretion in the diabetic patients, non-diabetic patients with chronic renal disease and normal control subjects is presented in Fig. 1 . Compared with normal control subjects, urinary excretion of NAG and DAP IV increased, whereas that of GGTP decreased significantly, in both diabetic and non-diabetic patients with renal failure. Increases in AAP and ALP excretion were significant only in diabetic patients with renal failure. It should be pointed out that excretion of NAG increased and excretion of GGTP decreased significantly in all the diabetic groups studied, including the NF/DM patients who had no evidence of renal dysfunction including microalbuminuria. When diabetic patients were compared with their appropriate azotaemic controls, IF/DM patients had significantly increased excretion of NAG, DAP IV and AAP compared with patients. However, all of the five enzymes showed similar excretion in RF/ DM and RF patients.
A correlation matrix for variables and urinary enzyme excretion is shown in Table 2 . There were high degrees of correlation between the excretion of NAG and glycaemic control (fasting plasma glucose concentration, HbAI,, urinary sugar), proteinuria (urinary protein, urinary microalbumin, urinary /?,-microglobulin), and glomerular function (serum creatinine concentration, creatinine clearance). NAG excretion was also closely correlated with the excretion of the other four enzymes. The excretion of GGTP showed high degrees of correlation with these variables; however, the directions were opposite to those for NAG excretion.
In an attempt to investigate further the causative factors of altered NAG and GGTP excretion, multiple regression analysis was performed. As a result, urinary protein and urinary sugar were identified as the major determinants of urinary NAG excretion, whereas creatinine clearance and HbA,, were the major determinants of GGTP excretion (Table 3) . Contribution rates (r') for NAG and GGTP excretion were 0.35 and 0.33, respectively. Table 4 summarizes the changes in diabetic control, blood pressure and renal function before and after diet therapy in diabetic patients and normal control subjects. It is clear that control of fasting blood glucose concentration and urinary sugar was achieved promptly, whereas other parameters were essentially unchanged. Changes in selected urinary enzyme excretion are shown in 
Study B effect of diet therapy on urinary enzyme excretion
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2. In NF/DM and IF/DM patients, NAG excretion was significantly decreased and GGTP excretion was significantly increased after diet therapy, indicating a tendency to normalization. In contrast, these changes were not apparent in RF/DM patients. AAP and DAP IV excretion showed little change after diet therapy. No significant changes in these parameters and in urinary enzyme excretion were noted in non-diabetic groups (IF and NF, data not shown).
DISCUSSION
Changes in urinary enzyme excretion have been reported in various diseases and toxic states [12, 131. There have been several studies in diabetes mellitus; however, most were on insulin-dependent (type I) diabetic patients or patients of either type [14-211. Although there are a number of advantages in studying type I diabetic patients [22], we studied type I1 diabetic patients because: (a) their prevalence is much higher among Japanese, and (b) acute changes in blood glucose concentration and urine flow rate, which are often seen in type I diabetic patients, are known to influence the urinary enzyme excretion rate [23-251. This study has shown that regardless of a diabetic or non-diabetic cause of renal dysfunction, urinary excretion of various enzymes originating in renal tubules is significantly affected. However, since there was a substantial overlap in enzyme excretion among the groups studied, tubular changes may not always parallel glomerular damage as previously expected. Abnormal enzymuria was generally more apparent in diabetic groups than in their appropriate non-diabetic control groups. Excretion of NAG and GGTP, in particular, changed significantly even in NF/DM patients, who were diabetic but had no signs of renal dysfunction including microalbuminuria. This result indicated that the hyperglycaemic state per se may contribute to tubular dysfunction and abnormal enzymuria. This view is further supported by our own finding that better glycaemic control and reduction in urinary sugar reversed the abnormal urinary excretion of NAG and GGTP.
Several potential metabolic pathways, such as non-enzymic glycosylation and sorbitol accumulation, have been proposed as a link between diabetes mellitus and its renal complications [26, 271. Since tubular cells have a high metabolic rate and are exposed to concentrated materials, they are presumed to be particularly vulnerable to those insults. Whatever the mechanism responsible, hyperglycaemia may be the trigger for a biochemical disturbance which leads to reversible functional changes, followed by irreversible structural changes [26] . From this point of view, the effect of diet therapy could be explained if tubular dysfunction was still reversible in NF/DM patients, whereas changes were irreversible in RF/DM patients. The predominance of structural changes may explain the similar enzyme excretion in RF/DM and R F patients. However, it has been demonstrated that high glucose levels activate some major signal transduction systems and affect growth rate, DNA synthesis and hormone and growth factor receptor turnover [27] . Therefore, it is possible that the abnormal enzymuria reflects the transient effects of hyperglycaemia rather than tubular injury. It is also possible that the relatively short-term treatment (2-4 weeks) or differences in the pretreatment metabolic control may have contributed to the lack of effect in some groups.
When applied to the overall data, multiple regression analysis revealed that the increased urinary protein is by far the most important factor determining urinary NAG excretion followed by urinary sugar. Filtered proteins are generally reabsorbed by adsorptive endocytosis at the apical border of tubular cells [28, 291 . When this system is stimulated, the release of hydrolases may occur before the endocytic vesicle has been completely pinched off and result in leakage of lysosomal enzymes. Using passive Heymann glomerulonephritic rats, Haga et al. [30, 311 have demonstrated that heavy proteinuria increased the number and the density of lysosomes. Therefore, with the progression of renal disease, increased filtered protein may accelerate the turnover rate of lysosomal systems and increase urinary NAG excretion. We observed a significant decrease in urinary GGTP excretion in patients with type I1 diabetes mellitus. This finding differs from the results of previous studies, which showed a slight increase or equivocal results [20, 213 . This discrepancy could be explained by the difference in patient selection (age, type I versus type 11, acute ketotic state versus chronic stable state) and in sample collection (spot urine versus 24 h urine collection). Although enzyme activities in spot urine are sometimes standardized in relation to creatinine concentration, we noticed that there was a tendency for diluted samples to show higher values by this method. Jung et al. [25] demonstrated increased excretion of brush-border enzymes during diuresis, and this increased enzyme excretion along with the diluted creatinine concentration might cause the distortion. The discrepancy between GGTP and the other brush-border enzymes deserves further attention. During tubular injury, brush-border surface glycoproteins, which contain various enzymes, are shed and released into the urine [32, 331. Although the shedding pattern of each enzyme may vary widely [25] , this is not a satisfactory explanation since it applies only for a short period. Other possible explanations are inactivation of GGTP or the presence of inhibitors. However, these possibilities could be excluded by keeping the samples at 4°C and by careful dialysis [12, 131 . Multiple regression analysis demonstrated that the reduced GGTP excretion was closely associated with a reduction in creatinine clearance; O u r preliminary studies on healthy kidney donors have also demonstrated decreased urinary GGTP excretion after one kidney had been removed (n=7, from 29.3k5.7 to 16.9 f 5.0 units/day, P < 0.05; H. Ikenaga et al., unpublished work). Furthermore, histochemical studies revealed a diffuse overall decrease in brushborder GGTP in patients undergoing chronic haemodialysis [34] . Combining these findings, it is likely that the expression of GGTP on the brushborder membranes and subsequent urinary excretion are closely related to the number of undamaged nephrons and their viability. Therefore, in a chronically detrimental condition such as diabetes mellitus, some brush-border enzymes with a high susceptibility or a low turnover rate may be depleted as a consequence of the continuous imbalance between synthesis and release, whereas other enzymes are still released in an increased amount. In more severe disease conditions, the expression of A A P and ALP was also found to be decreased [35] .
Measurement of urinary enzymes as diagnostic parameters of tubular dysfunction has not yet been generally accepted as a routine procedure. Many of the problems previously encountered in this field have resulted from the difficulties inherent in interpreting the findings in urine samples. However, these difficulties can be overcome by 24h urine collection and careful processing [36] . Measurement of urinary enzymes is non-invasive and inexpensive, and provides various aspects of renal function, especially tubular damage. Therefore, we propose that measurement of urinary enzymes, especially NAG and GGTP, would be useful in evaluating renal function. Applicability to other disease entities and the predictability of the disease process should be tested further.
